The First SPAC Dedicated to Meeting the Critical Demand for European Biomanufacturing

A Message from the CEO

"With this project, we will support the European development of one of the most promising sectors of the healthcare industry. Biotherapies and technological innovations from biopharmaceutical companies are destined to become key products in the treatment of many serious diseases for which no medical solution exists today. These innovations, and especially companies wishing to develop new treatments using these promising technologies, need to benefit from efficient and almost immediate logistical and industrial support, capable of providing them with the tools and production capacity necessary to pursue their clinical developments or to market their products. eureKING intends to assume this role by bringing together some of the most innovative European players in biomanufacturing to compete with the leading international companies and CDMOs".

Michael Kloss, eureKING CEO

"With this project, we will support the European development of one of the most promising sectors of the healthcare industry. Biotherapies and technological innovations from biopharmaceutical companies are destined to become key products in the treatment of many serious diseases for which no medical solution exists today. These innovations, and especially companies wishing to develop new treatments using these promising technologies, need to benefit from efficient and almost immediate logistical and industrial support, capable of providing them with the tools and production capacity necessary to pursue their clinical developments or to market their products. eureKING intends to assume this role by bringing together some of the most innovative European players in biomanufacturing to compete with the leading international companies and CDMOs".

Michael Kloss, eureKING CEO

Building a New European CDMO Major Player

*contract development and manufacturing organization

Leadership

A seasoned leadership team of biotech experts make up the operational team and Board

MICHAEL KLOSS

CEO and Co-Founder

STEFAN BERCHTOLD

Chief Finance Officer

PETER ECKENBERG

Chief Transformation and Strategy Officer

Corporate Sponsor

eureKARE is an investment company focused on financing and developing synthetic biology and microbiome innovation across Europe. Driven by the belief that synthetic biology holds the key to many of the world’s most pressing health and environmental challenges, eureKARE’s experienced team is focused on harnessing Europe’s untapped leadership in the field to build the companies of the future. eureKARE is championing a new model of startup creation and development to create a dynamic ecosystem of early and later stage ventures through its network of biotech studios. Backed by a proprietary AI tool, eureKARE’s  studios act as a bridge between academia and industry, helping to catalyze researchers’ innovations into companies with access to all the ingredients they need to grow, prosper, and bring benefits to society.

eureKING

128 rue de la Boétie, 75008 Paris, France

info@eureKING.com

Press Contacts

 

Nicolas Merigeau

+33 (0)1 44 71 94 98 

nmerigeau@newcap.fr 

Arthur Rouillé

+33 (0)1 44 71 00 15

arouille@newcap.fr